Kisspeptin-10 reverses obesity-diabetes effects by remodeling the gut-pancreatic axis in female mice | Research

The takeaway

Kisspeptin-10 normalized body weight, blood glucose, and energy intake in obese diabetic female mice while increasing GIP/GLP-1 positive gut cells, restoring islet architecture, and promoting beta-cell proliferation through gut-pancreatic axis modulation.

Beta-cell proliferation increased
Kisspeptin-10 not only normalized weight and glucose but promoted pancreatic beta-cell growth—a mechanism that could address the root cause of diabetes

What the researchers found

Kisspeptin-10: normalized body weight, glucose, energy intake. Increased GIP+ and GLP-1+ gut cells. Restored villi length, crypt depth. Restored insulin area and glucagon radius. Increased beta-cell proliferation. Enhanced FSH and LH. 21-day treatment, 25 nmol/kg IP.

Why it matters

This discovers a new metabolic function for kisspeptin that bridges reproductive and metabolic biology. By modulating both gut incretin cells and pancreatic beta-cells, kisspeptin could become a novel therapeutic target for obesity-diabetes.

How the study worked

High-fat diet obese diabetic female C57BL/6 mice. Kisspeptin-10 25 nmol/kg IP twice daily for 21 days. Immunohistochemistry for gut hormones and islet morphology. Hormonal profiling.

What this study cannot tell us

Mouse study only. Female mice only. Short treatment (21 days). IP injection not practical for humans. Dose optimization not explored. Mechanism of gut cell effects unclear.

How to read the evidence

Preclinical mouse study with comprehensive gut and pancreas analysis. Novel finding with strong data.

When this study was published

Published in 2025.

The bigger picture

The reproductive-metabolic axis is increasingly recognized as a therapeutic target. Kisspeptin's ability to improve both gut incretin cell populations and pancreatic function suggests it could complement GLP-1 drugs rather than compete with them.

Questions still open

Could kisspeptin analogues be developed for diabetes treatment?
Does kisspeptin have similar metabolic effects in males?
Would combining kisspeptin with GLP-1 drugs provide synergistic metabolic benefits?

Common questions

What is kisspeptin?

Kisspeptin is a neuropeptide best known for controlling puberty and reproduction. This study reveals it also has powerful metabolic effects—normalizing weight, blood sugar, and appetite in obese diabetic mice while improving the health of insulin-producing cells in the pancreas.

Could kisspeptin treat diabetes?

This study provides early evidence that it might. Kisspeptin-10 not only controlled weight and blood sugar but actually promoted the growth of insulin-producing beta-cells—addressing a fundamental problem in diabetes. However, this was in mice only; human studies are needed.

Read the original research

Kisspeptin-10 Ameliorates Obesity-Diabetes with Diverse Effects on Ileal Enteroendocrine Cells and Pancreatic Islet Morphology in High-Fat Fed Female Mice.

Biomolecules, 15(11)

View on PubMed ↗Publisher’s paper ↗

Citation

Sridhar, Ananyaa; Khan, Dawood; Muthukumar, Rithiga; Sampathkumar, Swetha; Irwin, Nigel; Flatt, Peter R; Moffett, R Charlotte. (2025). Kisspeptin-10 Ameliorates Obesity-Diabetes with Diverse Effects on Ileal Enteroendocrine Cells and Pancreatic Islet Morphology in High-Fat Fed Female Mice.. Biomolecules, 15(11). https://doi.org/10.3390/biom15111591